Clinical Pharmacology & Therapeutics, King's Health Partners, King's College Hospital, Denmark Hill, London, UK.
Br J Clin Pharmacol. 2013 Jan;75(1):36-44. doi: 10.1111/j.1365-2125.2012.04375.x.
Older people (those aged 65 years or over) comprise over 15% of the UK's population and this cohort is growing. Whilst at greatest risk from systemic arterial hypertension (hypertension), its resultant end organ damage and clinically significant cardiovascular disease, this group was initially neglected in clinical trials and thereby denied treatment, with the lack of evidence cited as justification. However since the 1960s, when the first landmark trials in severe diastolic hypertension were published, there has been a progressive attempt to understand the pathophysiology of hypertension and to expand the evidence base for treatment in older adults. In contrast to the participants of the very first randomized trials who had a mean age of 51 years, the recent Hypertension in the Very Elderly Trial demonstrated significant mortality and morbidity benefits from the treatment of both mixed systolic and diastolic hypertension, as well as isolated systolic hypertension in octogenarians. This review highlights the progressive evidence base behind the relative risks and benefits of treating hypertension in older adults.
老年人(65 岁或以上)占英国人口的 15%以上,且这一人群还在不断增加。虽然老年人患系统性动脉高血压(高血压)及其导致的靶器官损害和有临床意义的心血管疾病的风险最高,但最初临床试验并未将这一群体纳入研究,因此他们也被剥夺了治疗机会,缺乏相关证据则成为了不进行治疗的理由。然而,自 20 世纪 60 年代发表了首例严重舒张期高血压的标志性试验以来,人们一直在努力深入了解高血压的病理生理学,并扩大治疗老年人的循证医学基础。与最初随机试验的参与者平均年龄为 51 岁相比,最近的高龄老年人高血压试验(Hypertension in the Very Elderly Trial)表明,治疗混合性收缩期和舒张期高血压以及 80 岁以上老年人单纯收缩期高血压均能显著降低死亡率和发病率。本综述强调了治疗老年人高血压的相对风险和获益的循证医学基础不断发展。